HK1071379A1 - Long lasting fusion peptide inhibitors for hiv infection - Google Patents

Long lasting fusion peptide inhibitors for hiv infection

Info

Publication number
HK1071379A1
HK1071379A1 HK05104106A HK05104106A HK1071379A1 HK 1071379 A1 HK1071379 A1 HK 1071379A1 HK 05104106 A HK05104106 A HK 05104106A HK 05104106 A HK05104106 A HK 05104106A HK 1071379 A1 HK1071379 A1 HK 1071379A1
Authority
HK
Hong Kong
Prior art keywords
virus
hiv infection
long lasting
fusion peptide
peptide inhibitors
Prior art date
Application number
HK05104106A
Other languages
English (en)
Inventor
John Erickson
Dominique P Bridon
Martin Robitaille
Grant A Krafft
Dong Xie
Elena Afonina
Liangjun
Sandra De Meyer
Original Assignee
John Erickson
Conjuchem Biotechnologies Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by John Erickson, Conjuchem Biotechnologies Inc filed Critical John Erickson
Publication of HK1071379A1 publication Critical patent/HK1071379A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Genetics & Genomics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
HK05104106A 2001-05-31 2005-05-17 Long lasting fusion peptide inhibitors for hiv infection HK1071379A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US29424101P 2001-05-31 2001-05-31

Publications (1)

Publication Number Publication Date
HK1071379A1 true HK1071379A1 (en) 2005-07-15

Family

ID=23132509

Family Applications (1)

Application Number Title Priority Date Filing Date
HK05104106A HK1071379A1 (en) 2001-05-31 2005-05-17 Long lasting fusion peptide inhibitors for hiv infection

Country Status (12)

Country Link
US (2) US7741453B2 (es)
EP (1) EP1390399B1 (es)
JP (2) JP4463545B2 (es)
AT (3) ATE412667T1 (es)
AU (1) AU2002302277A1 (es)
CA (1) CA2448891A1 (es)
DE (3) DE60204137T2 (es)
DK (1) DK1479691T3 (es)
ES (2) ES2277173T3 (es)
HK (1) HK1071379A1 (es)
PT (1) PT1479691E (es)
WO (1) WO2002096935A2 (es)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2110381A1 (en) * 1999-05-17 2009-10-21 ConjuChem Biotechnologies Inc. Long lasting fusion peptide inhibitors of viral infection
US6887470B1 (en) 1999-09-10 2005-05-03 Conjuchem, Inc. Protection of endogenous therapeutic peptides from peptidase activity through conjugation to blood components
US6514500B1 (en) * 1999-10-15 2003-02-04 Conjuchem, Inc. Long lasting synthetic glucagon like peptide {GLP-!}
US20040266673A1 (en) * 2002-07-31 2004-12-30 Peter Bakis Long lasting natriuretic peptide derivatives
US7601691B2 (en) 1999-05-17 2009-10-13 Conjuchem Biotechnologies Inc. Anti-obesity agents
EP1180121B9 (en) * 1999-05-17 2004-09-08 Conjuchem, Inc. Long lasting insulinotropic peptides
US20090175821A1 (en) * 1999-05-17 2009-07-09 Bridon Dominique P Modified therapeutic peptides with extended half-lives in vivo
DK1360202T3 (da) * 2001-02-16 2008-09-22 Conjuchem Biotechnologies Inc Langvarigt glucagon-lignende peptid 2 (GLP-2) til behandling af gastrointestinale sygdomme og lidelser
EP1390399B1 (en) 2001-05-31 2005-05-11 Conjuchem, Inc. Long lasting fusion peptide inhibitors for hiv infection
US20070207952A1 (en) * 2003-03-24 2007-09-06 Sequoia Pharmaceuticals Long Acting Biologically Active Conjugates
US20090123468A1 (en) 2003-10-24 2009-05-14 Gencia Corporation Transducible polypeptides for modifying metabolism
EP1687017B1 (en) 2003-10-24 2013-03-06 Gencia Corporation Methods and compositions for delivering polynucleotides
US8062891B2 (en) 2003-10-24 2011-11-22 Gencia Corporation Nonviral vectors for delivering polynucleotides to plants
US8507277B2 (en) 2003-10-24 2013-08-13 Gencia Corporation Nonviral vectors for delivering polynucleotides
US8133733B2 (en) 2003-10-24 2012-03-13 Gencia Corporation Nonviral vectors for delivering polynucleotides to target tissues
PL1745078T3 (pl) * 2004-04-23 2009-12-31 Conjuchem Biotechnologies Inc Sposób oczyszczania koniugatów albumin
WO2005108418A1 (en) * 2004-05-06 2005-11-17 Conjuchem Biotechnologies Inc. Compounds for specific viral target
US8039432B2 (en) * 2005-11-09 2011-10-18 Conjuchem, Llc Method of treatment of diabetes and/or obesity with reduced nausea side effect
JP2009520469A (ja) * 2005-12-22 2009-05-28 コンジュクヘム ビオテクフノロギエス インコーポレイテッド アルブミンと治療薬との前もって形成された抱合体の産生のための方法
US20090099074A1 (en) * 2007-01-10 2009-04-16 Conjuchem Biotechnologies Inc. Modulating food intake
US20090088378A1 (en) * 2007-01-12 2009-04-02 Omar Quraishi Long lasting inhibitors of viral infection
CN101687911A (zh) * 2007-05-16 2010-03-31 康久化学生物技术公司 抗病毒肽的半胱磺酸衍生物
WO2008144590A2 (en) * 2007-05-16 2008-11-27 Conjuchem Biotechnologies Inc. Long lasting modified antifusogenic peptide for preventing hiv infection
GB0720503D0 (en) * 2007-10-22 2007-11-28 Angeletti P Ist Richerche Bio New compound
US20090186819A1 (en) * 2007-12-11 2009-07-23 Marieve Carrier Formulation of insulinotropic peptide conjugates
US8815295B1 (en) 2011-12-22 2014-08-26 Alabama State University Anti respiratory syncytial virus peptide functionalized gold nanoparticles
AU2013263349B2 (en) 2012-05-17 2016-09-08 Extend Biosciences, Inc Carriers for improved drug delivery
US9789197B2 (en) 2014-10-22 2017-10-17 Extend Biosciences, Inc. RNAi vitamin D conjugates
WO2016065052A1 (en) 2014-10-22 2016-04-28 Extend Biosciences, Inc. Insulin vitamin d conjugates
CA2964463C (en) 2014-10-22 2024-02-13 Extend Biosciences, Inc. Therapeutic vitamin d conjugates

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4652629A (en) 1985-07-03 1987-03-24 The Salk Institute For Biological Studies Synthetic peptide-based anti-rabies compositions and methods
US5612034A (en) 1990-10-03 1997-03-18 Redcell, Inc. Super-globuling for in vivo extended lifetimes
FR2686899B1 (fr) 1992-01-31 1995-09-01 Rhone Poulenc Rorer Sa Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant.
JP4010560B2 (ja) 1992-07-20 2007-11-21 ドューク ユニバーシティー Ｈｉｖ複製を阻害する化合物
GB9316895D0 (en) 1993-08-13 1993-09-29 Guy S And St Thomas Hospitals Hepatoselective insulin analogues
EP0602290B1 (en) 1992-12-04 1999-08-25 ConjuChem, Inc. Antibody-conjugated Hepatitis B surface antigen and use thereof
US5614487A (en) 1993-05-28 1997-03-25 Genentech, Inc. Sustained release pharmaceutical composition
US6017536A (en) 1993-06-07 2000-01-25 Trimeris, Inc. Simian immunodeficiency virus peptides with antifusogenic and antiviral activities
US6479055B1 (en) 1993-06-07 2002-11-12 Trimeris, Inc. Methods for inhibition of membrane fusion-associated events, including respiratory syncytial virus transmission
US6342225B1 (en) 1993-08-13 2002-01-29 Deutshces Wollforschungsinstitut Pharmaceutical active conjugates
WO1996005389A1 (en) 1994-08-15 1996-02-22 B-Level Corp. Auxiliary surface-forming member for construction elements
US6103236A (en) 1995-05-10 2000-08-15 Kyowa Hakko Kogyo Co., Ltd. Toxin conjugates
US6576636B2 (en) 1996-05-22 2003-06-10 Protarga, Inc. Method of treating a liver disorder with fatty acid-antiviral agent conjugates
US6150088A (en) * 1997-04-17 2000-11-21 Whitehead Institute For Biomedical Research Core structure of gp41 from the HIV envelope glycoprotein
AU1519799A (en) 1997-11-07 1999-05-31 Conjuchem, Inc. Salicylate derivatized therapeutic and diagnostic agents
CA2305597C (en) 1997-11-07 2008-07-29 Conjuchem Inc. Affinity markers for human serum albumin
US6107489A (en) 1998-03-17 2000-08-22 Conjuchem, Inc. Extended lifetimes in vivo renin inhibitors
EP1042003A1 (en) 1998-03-23 2000-10-11 Conjuchem, Inc. Delivery of long lasting therapeutic agents by forming covalent attachments in vivo
US6656906B1 (en) 1998-05-20 2003-12-02 Trimeris, Inc. Hybrid polypeptides with enhanced pharmacokinetic properties
US6258782B1 (en) * 1998-05-20 2001-07-10 Trimeris, Inc. Hybrid polypeptides with enhanced pharmacokinetic properties
AU773428B2 (en) 1998-10-13 2004-05-27 Peptide Biosciences, Inc. Stabilized bioactive peptides and methods of identification, synthesis and use
US20030190740A1 (en) 1998-10-13 2003-10-09 The University Of Georgia Research Foundation, Inc Stabilized bioactive peptides and methods of identification, synthesis, and use
AU2604200A (en) 1999-01-08 2000-07-24 Panacos Pharmaceuticals, Inc. Methods of eliciting broadly neutralizing antibodies targeting hiv-1 gp41
EP1105409B1 (en) 1999-05-17 2006-03-01 Conjuchem, Inc. Protection of endogenous therapeutic peptides from peptidase activity through conjugation to blood components
AU764103B2 (en) 1999-05-17 2003-08-07 Conjuchem Biotechnologies Inc. Long lasting anti-angiogenic peptides
EP1180121B9 (en) 1999-05-17 2004-09-08 Conjuchem, Inc. Long lasting insulinotropic peptides
EP2110381A1 (en) 1999-05-17 2009-10-21 ConjuChem Biotechnologies Inc. Long lasting fusion peptide inhibitors of viral infection
US20090175821A1 (en) 1999-05-17 2009-07-09 Bridon Dominique P Modified therapeutic peptides with extended half-lives in vivo
DE19926154A1 (de) 1999-06-09 2000-12-14 Ktb Tumorforschungs Gmbh Verfahren zur Herstellung einer injizierbaren Arzneimittelzubereitung
DE19926475A1 (de) 1999-06-10 2000-12-14 Ktb Tumorforschungs Gmbh Träger-Pharmaka-Konjugate
CA2383798A1 (en) 1999-09-07 2001-03-15 Conjuchem Inc. Pulmonary delivery for bioconjugation
US7090851B1 (en) 1999-09-10 2006-08-15 Conjuchem Inc. Long lasting fusion peptide inhibitors of viral infection
JP4925540B2 (ja) 1999-12-16 2012-04-25 ホワイトヘッド インスチチュート フォアー バイオメディカル リサーチ ５−ヘリックスタンパク質
EP1390399B1 (en) 2001-05-31 2005-05-11 Conjuchem, Inc. Long lasting fusion peptide inhibitors for hiv infection
AU2003275116A1 (en) 2002-09-24 2004-04-19 Frontier Biotechnologies Co., Ltd Peptide derivative fusion inhibitors of hiv infection
CN101152573A (zh) 2002-09-27 2008-04-02 唐纳士公司 用于预防和治疗获得性免疫缺陷综合症的协同组合物
US7556813B2 (en) 2002-09-27 2009-07-07 Trimeris, Inc. Antiviral peptide-polymer conjugate comprising a polymer covalently attached to two or more synthetic HIV gp41 HR1 and/or HR2 peptides
US20050113292A1 (en) 2003-07-18 2005-05-26 Vanderbilt University Compositions of protein mimetics and methods of using same against HIV-1, SARS-coV and the like
PL1745078T3 (pl) 2004-04-23 2009-12-31 Conjuchem Biotechnologies Inc Sposób oczyszczania koniugatów albumin
WO2005108418A1 (en) 2004-05-06 2005-11-17 Conjuchem Biotechnologies Inc. Compounds for specific viral target
JP2009520469A (ja) 2005-12-22 2009-05-28 コンジュクヘム ビオテクフノロギエス インコーポレイテッド アルブミンと治療薬との前もって形成された抱合体の産生のための方法

Also Published As

Publication number Publication date
ATE295370T1 (de) 2005-05-15
DE60204137D1 (de) 2005-06-16
US20050065075A1 (en) 2005-03-24
EP1390399A2 (en) 2004-02-25
WO2002096935A2 (en) 2002-12-05
US20110166061A1 (en) 2011-07-07
DE60204137T2 (de) 2006-01-26
ES2277173T3 (es) 2007-07-01
JP2005500274A (ja) 2005-01-06
ATE412667T1 (de) 2008-11-15
PT1479691E (pt) 2007-02-28
ES2242860T3 (es) 2005-11-16
DE60216151T2 (de) 2007-09-27
ATE345353T1 (de) 2006-12-15
DE60216151D1 (de) 2006-12-28
JP4463545B2 (ja) 2010-05-19
DK1479691T3 (da) 2007-03-12
EP1390399B1 (en) 2005-05-11
US7741453B2 (en) 2010-06-22
AU2002302277A1 (en) 2002-12-09
DE60229677D1 (de) 2008-12-11
WO2002096935A3 (en) 2003-10-02
JP2008308506A (ja) 2008-12-25
CA2448891A1 (en) 2002-12-05

Similar Documents

Publication Publication Date Title
HK1071379A1 (en) Long lasting fusion peptide inhibitors for hiv infection
WO2008144584A3 (en) Cysteic acid derivatives of anti-viral peptides
DE69738535D1 (de) Antivirale mittel aus pflanzenextrakten und deren verwendung zur behandlung viraler infektionen
ATE476983T1 (de) Immunostimulierende polynukleotide sequenzen zur verwendung bei der verhinderung und behandlung von viralen erkrankungen der atemwege
WO2005007078A3 (en) Method of inhibiting human metapneumovirus and human coronavirus in the prevention and treatment of severe acute respiratory syndrome (sars)
WO2003051306A3 (en) N4-acylcytosine-1,3-dioxolane nucleosides for treatment of viral infections
NO20051969L (no) Nukleosidderivater for behandling av hepatitt C virusinfeksjon.
WO1998001144A2 (en) Antiviral agents from plant extracts and use for treatment of viral infections
EA200700243A1 (ru) Способы лечения гепатита с
DE602006015861D1 (de) Antivirale verbindungen
WO2007033444A3 (en) Antiviral therapy with carbohydrate binding agents
WO2001010456A3 (en) Peptides that block viral infectivity and methods of use thereof
WO2003053344A3 (en) Substituted 2-methyl-benzimidazole respiratory syncytial virus antiviral agents
WO2008118849A3 (en) Hiv-1 protease inhibitors
CR7806A (es) Inhibidores de la fusion de derivados peptidos de la infeccion vih
DE602005016552D1 (de) Parapocken-viren in kombination mit anderen antiviralen mitteln zur behandlung von hiv/aids
WO2006045616A3 (en) β-L-N4-HYDROXYCYTOSINE DEOXYNUCLEOSIDES AND THEIR USE AS PHARMACEUTICAL AGENTS IN THE PROPHYLAXIS OR THERAPY OF VIRAL DISEASES
WO2007002172A3 (en) Hiv-1 protease inhibitors
WO2004052905A3 (en) Antiviral nucleoside derivatives
EP1752469A3 (en) Long lasting fusion peptide inhibitors for HIV infection
ATE478679T1 (de) Verfahren zur anwendung von ionisierungsstrahlung bei einer hiv-infektionstherapie
WO2008144590A3 (en) Long lasting modified antifusogenic peptide for preventing hiv infection
ATE375800T1 (de) Anti-hiv und anti-tumor lysozympeptide sowie fragmente
CY1105997T1 (el) Mακρας διαρκειας αναστολεις πεπτιδιου συντηξης για μολυνση hiv
ATE481413T1 (de) Glutathionderivate und deren verwendung zur behandlung von viralen erkrankungen

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20120531